Home » Stocks » BMRA

Biomerica, Inc. (BMRA)

Stock Price: $7.37 USD 0.39 (5.59%)
Updated Jan 25, 2021 3:33 PM EST - Market open
Market Cap 82.23M
Revenue (ttm) 6.42M
Net Income (ttm) -4.48M
Shares Out 11.76M
EPS (ttm) -0.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $7.37
Previous Close $6.98
Change ($) 0.39
Change (%) 5.59%
Day's Open 7.29
Day's Range 6.80 - 7.70
Day's Volume 775,545
52-Week Range 2.37 - 16.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

IRVINE, Calif., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced financial results for its second quarter of fi...

InvestorPlace - 1 week ago

Biomerica (BMRA) news for Tuesday concerning its rapid test for the novel coronavirus coming to new countries has BMRA stock on the rise. The post Biomerica News: 10 Things for Potential BMRA ...

GlobeNewsWire - 1 week ago

IRVINE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced it has received CE Mark for its new COVID-19 R...

GlobeNewsWire - 1 month ago

IRVINE, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced it is nearing completion of patient enrollment...

GlobeNewsWire - 3 months ago

IRVINE, Calif., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported financial results for the fiscal quarter ended ...

GlobeNewsWire - 4 months ago

IRVINE, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year ended May 31, ...

GlobeNewsWire - 4 months ago

IRVINE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced today the retirement of Janet Moore, the Company’s Chief Financial Officer. After many years o...

GlobeNewsWire - 5 months ago

IRVINE, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for Biomer...

GlobeNewsWire - 6 months ago

IRVINE, Calif., July 22, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that it has filed a new three year shelf registration statement on Form S-3 with the United St...

InvestorPlace - 6 months ago

Here are seven cheap stocks to buy in the second half of the year. They come with risk, but are likely to offer head-turning reward potential, too.

Other stocks mentioned: AEG, FUV, GAIA, GTX, HMY, NMR
Seeking Alpha - 6 months ago

Biomerica's COVID-19 Test Ignite The Market

GlobeNewsWire - 6 months ago

IRVINE, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced it has signed a definitive agreement with the University of Texas Health Science Center at Hou...

GlobeNewsWire - 7 months ago

IRVINE, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today they have submitted to the FDA an EUA application for an ELISA lab-based serology blood test f...

GlobeNewsWire - 7 months ago

IRVINE, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced they have signed definitive agreements with Mayo Clinic to join the clinical trial for Biomeri...

GlobeNewsWire - 8 months ago

IRVINE, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced it has received a CE mark and launched a new high-volume production version of its COVID-19 IgG...

Benzinga - 9 months ago

Biomerica, Inc. (NASDAQ: BMRA) shares are trading higher after the company announced it has signed two definitive agreements with Mount Sinai Medical School in NY to scale-up a laboratory vers...

GlobeNewsWire - 9 months ago

IRVINE, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced it has signed two separate definitive license agreements with Mount Sinai’s Icahn School of M...

Benzinga - 10 months ago

Shares of micro-cap Biomerica, Inc. (NASDAQ: BMRA) were advancing strongly for the second straight session Thursday thanks to a late Tuesday announcement from the biomedical technology company...

GlobeNewsWire - 10 months ago

IRVINE, Calif., March 17, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced it has commenced shipping initial samples of its COVID-19 IgG/IgM Rapid Test (a finger prick ...

GlobeNewsWire - 10 months ago

IRVINE, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) (the “Company” or “Biomerica”) announced today that the Company completed a private placement of $2 million of...

GlobeNewsWire - 1 year ago

IRVINE, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) --  Biomerica Inc. (NASDAQ: BMRA) today announced that Houston Methodist (part of Texas Medical Center, the largest medical complex in the worl...

GlobeNewsWire - 1 year ago

IRVINE, Calif., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) today reported net sales of $1,194,415 for the three months ending August 31, 2019, compared to $1,272,870 fo...

GlobeNewsWire - 1 year ago

IRVINE, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2019 were $5,20...

GlobeNewsWire - 1 year ago

Biomerica also adds new director of sales and marketing for Europe and South America Biomerica also adds new director of sales and marketing for Europe and South America

About BMRA

Biomerica, a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools o... [Read more...]

Industry
Diagnostics & Research
Founded
1971
CEO
Zackary S. Irani
Employees
65
Stock Exchange
NASDAQ
Ticker Symbol
BMRA
Full Company Profile

Financial Performance

In 2020, Biomerica's revenue was $6.69 million, an increase of 28.69% compared to the previous year's $5.20 million. Losses were -$2.34 million, -2.26% less than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Biomerica stock is "Strong Buy." The 12-month stock price forecast is 10.88, which is an increase of 47.63% from the latest price.

Price Target
$10.88
(47.63% upside)
Analyst Consensus: Strong Buy